MSHLPolatuzumab vedotin Powder For Concentrate For Solution For Infusion 30 mg, 140 mg
1) Polatuzumab in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.
2) Polatuzumab in combination with rituximab (non-subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.
3) Polatuzumab in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL).